Synthesis and Antimicrobial Screening of Some Novel 2-amino Benzothiazole Derivatives

A couple of new N-3-chloropropyl-benzothiazole-2-amine derivatives (Compound B1, B2) and N-benzothiazol-2-yl)-2-chloroacetamide derivatives (Compound A1, A2) were the focus of the current investigation. In the presence of TEA, 2-aminobenzothiazole and 2-chloroacetyl chloride were combined to form the intermediate molecule N-benzothiazol-2-yl)-2- chloroacetamide, also known as Intermediate X1. Through the reaction of Intermediate X1 with sulfanilic acid and sulphanilamide, the final compounds (Compounds A1 and A2) were produced. 2-Aminobenzothiazole and 1-Bromo-3-chloropropane were combined with TEA to form the intermediate chemical N-3-chloropropyl-benzothiazole-2-amine, also known as Intermediate Y1. Intermediate Y1 was reactated with sulfanilic acid and sulphanilamide to produce the final chemicals (Compound B1, B2). The spectroscopic approach was used to characterize the synthesized compounds, and TLC and melting point were used to evaluate the purity of all the compounds. The anti-microbial activity of the produced compounds was tested. According to the findings, most compounds exhibited a smaller or nonexistent zone of inhibition against bacteria in comparison to the gold standard medication, Norfloxacin. Out of all the compounds that were produced, at concentrations. In comparison to the gold standard antibiotic Norfloxacin, compound A1 had a smaller zone of inhibition (ZOI) against gram-positive Bacillus subtilis (22 mm, 28 mm, and 33 mm diameter, respectively), measuring 38 mm, 42 mm, and 48 mm diameter. The compound A2 exhibited the largest zone of inhibition (21 mm, 26 mm, and 33 mm diameter) when tested against the gram-positive Bacillus subtilis bacteria at concentrations. However, this was still lower than the standard drug Norfloxacin, which had ZOIs of 38 mm, 42 mm, and 48 mm diameter, respectively. Compound B1 exhibited the largest zone of inhibition (20 mm, 24 mm, and 26 mm diameter) when tested against Bacillus subtilis (a gram-positive bacterium) at concentrations. However, this was lower than the standard drug Norfloxacin (ZOI-38 mm, 42 mm, and 48 mm diameter). Compound B1 had the largest zone of inhibition (22 mm, 25 mm, and 28 mm diameter) out of all the synthesized compounds tested with a diameter of 26 mm, 32 mm, and 36 mm, respectively), but not as effective as the gold standard antibiotic Norfloxacin against gram- inhibition (ZOI) against Escherichia coli (a gram-negative bacteria) at concentrations of 100 µg/ml, 200 µg/ml, and 300 µg/ml, with respective diameters of 20 mm, 22 mm, and 25 mm respectively.